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1. Introduction
Type 2 diabetes (T2D) is the world’s fastest growing disease with high morbidity and mortality
rates. The potential to develop effective therapies is severely limited by poor understanding
of mechanisms underlying the etiology and progression of T2D.
Increasing evidence suggests that the brain plays a key role in regulating metabolism [1, 2]. In
particular, the exquisitely precise adjustments in the sympathetic and parasympathetic
outflow by the brain are critical for maintaining metabolic homeostasis. Enhanced sympathetic
drive and impaired vagal efferent function contribute to multisystemic pathophysiology of
T2D, including reduced insulin secretion, gastroparesis, hypertension, and high cardiovascu‐
lar mortality [3-6]. The aim of this chapter is to emphasize the importance of the brainstem,
which contains sympathovagal regulatory nuclei, in the regulation of metabolism, especially
in T2D conditions. I focus on the role of b ainstem thyrotropin-releasing hormone (TRH) in the
physiology of autonomic control of metabolism and the pathophysiology of autonomic
dysfunction in T2D. TRH is a three amino acid neuropeptide originally discovered in the
hypothalamic paraventricular nucleus. Brainstem raphe nuclei are another major locus of TRH
neurons, which send TRH-containing projections to innervate brainstem and spinal sympa‐
thetic and vagal motor/premotor nuclei. TRH acts at these nuclei to control sympathetic and
vagal descending pathways involved in regulating food intake, blood pressure, heart beat,
pancreatic insulin secretion, and gastrointestinal secretion/motility. Our studies found an
impaired brainstem TRH action on the vagal efferent control in a T2D rat model. Understand‐
ing brainstem disorders responsible for the sympathovagal imbalance in T2D is fundamental
for revealing the mechanism of T2D development. Targeting on restoring a balanced sympa‐
thetic-vagal regulatory function of brainstem TRH could be a new direction for the prevention
and therapy of T2D.
© 2013 Hong; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. The autonomic nervous system is a major pathway mediating the brain
regulation of metabolism
2.1. Sympathovagal motor and premotor neurons in the brainstem and the spinal cord
The sympathetic and parasympathetic nerves are the two functionally opposite branches
innervating visceral organs to mediate and integrate the central control of body metabolism.
While numerous studies have well established the metabolic regulatory center of the hypo‐
thalamus, more and more recent studies revealed the importance of the brainstem in the
neuroanatomically distributed control of energy balance [7]. Studies by Grill et al using the
chronically decerebrate rat models demonstrated that the brainstem, also called hindbrain,
contains an essential mechanism detecting metabolic need and exhibiting autonomic response
to the metabolic challenge [7-9]. The brainstem is sufficient to mediate many aspects of the
energetic response to starvation and maintain the normal glucose levels [10]. Indeed, the
brainstem contains neural circuits receiving and sensing peripheral neural, nutritional and
hormonal signals, and more importantly, including sympathovagal motor neurons and
premotor neurons responding to these signals.
2.1.1. The Dorsal Vagal Complex (DVC) and the nucleus Ambiguus (Amb)
The DVC is composed of the dorsal motor nucleus of the vagus (DMV) and the nucleus tractus
solitarii (NTS) (Fig.1), which respectively contains somata of parasympathetic efferents
projecting to the visceral organs [11-13] and neurons receiving vagal afferent input from the
viscera [14]. The nearby area postrema (AP) and portions of the NTS, where the blood-brain
barrier is incomplete, can be the portal of entry for circulating hormones entering the brain [15].
The Amb contains vagal motor neurons projecting to the thoracic organs as well as the upper
gastrointestinal (GI) tract and the pancreas (Fig. 1).
The DMV receives  powerful  influence from higher  brain levels.  Stimulation of  the neu‐
rons in the paraventricular  nucleus of  the hypothalamus (PVN) activates  DMV neurons
projecting to the gut [16,17]. The ventromedial hypothalamic nucleus (VMH), which con‐
tains glucose sensitive neurons, also has direct connections with DMV and NTS [18,19]. In
addition, the DMV receives descending connections from the locus coeruleus (LC), which
is the origin of the noradrenergic innervation of the preganglionic autonomic nuclei in the
medulla oblongata [20].
Vagal afferent fibers arise from neurons in the nodose ganglia and their central and peripheral
terminals are located respectively in the NTS and visceral organs. A number of NTS neurons
directly, or indirectly via interneurons, connect with vagal motor neurons in the DMV, forming
vago-vagal reflex, which may result in increased or decreased vagal efferent activity, and thus
is an important component in the brainstem circuits controlling the vagal efferent function,
independent of the higher brain [21-23].
Acetylcholine is the major transmitter of vagal preganglionic motoneurons in the DMV, which
contains intense choline acetyltransferase (ChAT) [24]. By retrograde tracing of subdiaphrag‐
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matic vagus, the majority (52%) of labeled DMV cells is ChAT positive [25]. Nitric oxide (NO)-
synthesizing neurons are identified in the DMV as vagal motoneurons projecting to the GI
tract and also in the NTS [26,27]. These neurons are involved in the gastric receptive relaxation
reflex [26]. The catecholaminergic NTS neurons are tyrosine hydroxylase (TH) positive that
relay the signals received by the NTS to other brain structures [28].
2.1.2. The spinal intermediolateral cell column (IML) and the rostral ventrolateral medulla (RVLM)
The sympathetic preganglionic motor neurons are located in the IML of the spinal cord. A
group of brainstem neurons in the RVLM are sympathetic premotor neurons that project
monosynaptically to the IML. Brainstem RVLM is the final common point of convergence of
most brain pathways regulating sympathetic tone controlling functions of multisystemic
visceral organs [29, 30]. The efferent projections of the catecholamine neurons in the C1 area
of the RVLM display important central control of the cardiovascular regulation [31]. Trans‐
neuronal labeling studies also showed that the RVLM is a major brain region involved in
sympathetic control of the pancreas [32].
Figure 1. Coronal barainstem section (interaural-4.68 mm) showing the location of THR neurons and THR terminals,
and THR regulation of sympathovagal functions.
2.2. sympathovagal-efferent regulation of pancreatic islet hormones secretion and food
intake
The autonomic nervous system plays a fundamental role in the brain regulation of metabolism,
as this system innervates and tightly controls multisystemic organs involved in food intake
and digestion, nutrition absorption, peripheral hormone secretion, blood circulation, and
metabolic waste excretion. Here we focus on the pancreatic endocrine secretion and food
intake.
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2.2.1. Brain regulation of pancreatic endocrine secretion through vagal and sympathetic nerves
The central nervous system requires glucose as an essential source of energy. To maintain
blood glucose levels within a narrow range, the brain regulates pancreatic endocrine secretion
through rich innervation of vagal and sympathetic nerves in the islets [33]. In rats, three of the
five vagal branches, the posterior gastric, anterior gastric, and the hepatic branches, mediate
insulin secretion [34]. The direct sympathetic innervation of the pancreas comes from the
sympathetic chains and splanchnic and celiac ganglia [35]. Insulin secretion is stimulated by
vagal activation and inhibited by sympathetic-adrenal activation [36]. The integrity of vagus-
cholinergic component plays an important role in pancreatic islet proliferation and insulin
secretion of the cephalic phase and during the early absorption period, and is necessary to
maintain normal glucose tolerance [33, 37-40]. Impairment in glucose tolerance is frequently
observed in pancreas-transplanted patients due to denervation of the grafted pancreas. These
patients have a high basal invariant insulin levels but a reduced insulin secretory capacity in
response to glucose challenge; cephalic phase insulin release is absent [41-43]. Decreased β-
cell mass was observed in dogs undergone pancreas-transplantation [44]. Acetylcholine is the
major neurotransmitter of the vagus nervous and M3 receptor represents the major muscarinic
receptor that is functional in pancreatic β-cells [36, 45, 46]. Mutant mice selectively lacking M3
receptor in pancreatic β-cells display impaired glucose tolerance and greatly reduced insulin
release. In contrast, mice selectively overexpressing M3 receptors in β-cells show a profound
increase in glucose tolerance and insulin release. Moreover, the β-cell M3-overexpressing mice
are resistant to diet-induced glucose intolerance and hyperglycemia [47]. These findings
indicate that autonomic nerves play a key role in maintaining proper insulin release and
glucose homeostasis.
2.2.2. The importance of the vagus nerve in food intake regulation
Food intake provides body energy. Autonomic innervation, especially cholinergic processes
of the vagus control hunger, meal initiation, and food digestion. Vagal-cholinergic (muscar‐
inic) activation regulates gastric ghrelin biosynthesis and secretion [48, 49]. Elevation of plasma
ghrelin induced by food deprivation can be blocked by subdiaphragmatic vagotomy and
atropine treatment [50]. Circulating ghrelin levels in humans are increased or reduced by
cholinergic agonists or antagonists, respectively [51].
2.3. Brainstem sympathovagal-controlling circuits respond to metabolic alterations
Hypoglycemia is a well established central stimulus that enhances autonomic activities [52-55].
The neuronal activations in the PVN, DVC and other autonomic-regulatory nuclei are initiated
when blood glucose levels are immediately below the normal range; the extent of neuronal
activation negatively correlates with glucose levels [55]. Microinjection of glucose into the DVC
prevents hypoglycemia-induced gastric motility response, indicating a direct influence of
glucose concentration on the DVC neurons [56, 57]. Acute glucose deprivation by 2-deoxy-
glucose induces Fos expression in NADPH-positive neurons in the NTS and DMV [58] and in
catecholamine neurons in the RVLM [59]. Electrophysiological data suggest that some DMV
neurons have an enteroceptor function detecting changes in glucose concentration in their
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environment [60]; however, another study found that glucose had no direct effect on DMV
neurons, which appear to be affected by glucose action on NTS neurons [61]. The NTS neurons
transmit information of local glucose availability and peripheral glucose metabolic signals
received from the vagal afferents toward other brain areas, such as the nearby DMV, via circuits
mediating vagal-vagal reflex, and the hypothalamus, including the PVN, via the ascending
adrenergic and noradrenergic pathways [61-64]. The response of medullary vagal-regulatory
circuits to altered blood glucose levels seems independent of the higher brain structures. In
dogs, decerebration and mid-brain or pontine section did not prevent insulin-hypoglycemia-
induced gastric acid secretion, which was drastically reduced after destruction of the DMV
[65]. Beside the enhanced vagal efferent outflow, which mediates hypoglycemia induced food
intake, neuronal activation in the RVLM by glucose deprivation increases sympathetic efferent
activity [59], which is important for the liver to produce and release more glucose. These
findings indicate that activating brainstem autonomic regulatory circuits is an important
counterregulatory response for changed metabolic status.
3. Brainstem Thyrotropin-Releasing Hormone (TRH)-containing circuits
regulate sympathovagal outflow to visceral organs
3.1. Brainstem TRH synthesizing neurons and their projections to the autonomic motor/
premotor nuclei
TRH is a three amino acid neuropeptide originally discovered in the hypothalamic PVN, where
it regulates pituitary thyrotropin release. Brainstem raphe nuclei, including the raphe pallidus
(Rpa), raphe obscurus (Rob) and the parapyramidal regions (PPR) are among other major loci
capable of TRH synthesis in the brain (Fig.1). Raphe nuclei project TRH-containing fibers to
sympathetic and vagal motor neurons located respectively in the brainstem DVC, the RVLM,
and the spinal IML, areas densely clustered with TRH-immunoreactive nerve terminals and
TRH receptor 1 [66-69] (Figs.1,2). Electron microscopic studies revealed that TRH terminals
make direct synaptic contacts with dendrites of neurons in medial NTS and vagal motoneurons
throughout the DMV [68]. The direct effects of TRH are to excite DMV neurons and inhibit
NTS neurons [70]. TRH-containing fibers also innervate sympathetic premotor loci, particu‐
larly the RVLM [69, 71, 72]. These TRH-containing brainstem-spinal circuits are important
central components of autonomic regulation of visceral organ functions and in particular, the
baroreflex pathways [73].
3.2. Brainstem TRH regulation of gastric, pancreatic, and cardiovascular functions
Studies in the 1980s by Amir S et al and others found that intracerebroventricular (icv) injection
of TRH induces hyperglycemia through pathways involving the adrenal gland in rats, but
prevents central and peripheral stimuli-induced hyperglycemia in mice through stimulating
insulin release [74-78].
Our studies demonstrated that injection of TRH or its stable analog RX77368 into brain
ventricles activates both sympathetic and vagal descending pathways, inducing sympatheti‐
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cally driven hyperglycemia, hypertension and tachycardia, and vagally mediated stimulation
of gastric secretion/contractility, pancreatic insulin secretion, and ghrelin release [49, 69, 79-82].
The gastric myenteric plexus innervates smooth muscle and mucosal layers and receives dense
and intricate network of vagal efferent axons [83-86]. Electrical stimulation of the rat cervical
vagus nerve induces widespread Fos expression in the gastric myenteric plexus in rats [87,
88]. Similarly, intracisternal injection of TRH analog, known to activate vagal preganglionic
neurons in the DMV and increase gastric vagal efferent discharges [80, 89,90], activates gastric
myenteric neurons in rats [91]. Brainstem microinjection and intrathecal (it) injection studies
revealed that pontine locus coeruleus, brainstem RVLM and spinal IML are TRH action sites
for activating sympathetic efferent pathways [69, 79, 92, 93], whereas the DMV, the Amb, and
the dorsal portion of the RVLM are among those responsible for the resulting stimulation of
vagal efferent outflow [69, 94-96]. Substantial evidence shows that TRH is the only brain
peptide fulfilling all of the criteria as a neurotransmitter and/or neuromodulator activating
vagal motor neurons in the DMV [49, 69, 80, 82, 97]. TRH knockout mice are significantly
hyperglycemic with impaired insulin secretion in response to glucose [98].
3.3. Physiological and pathophysiological regulation of brainstem TRH gene expression
Autonomic response to external and internal environmental changes is associated with
activation of brainstem TRH containing pathways. Brainstem TRH gene expression is upre‐
gulated by energy deficiency or increased energy demand, such as starvation, hypothermia,
and hypothyroidism [49, 99, 100].
Figure 2. PreproTHR-containing fibres (green) and ChAT neurons (red) in the DMV and TH neurons (red) in the RLVM
and NTS.
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The physiological role of brainstem TRH in regulating sympathovagal efferent activities
responding to metabolic challenge was first evidenced in the animal model of cold exposure,
which is wildly used to induce sympathetic-vagally mediated gastric ulceration [99, 101, 102].
Cold exposure activates not only TRH system in the hypothalamus but also TRH-containing
Rpa/Rob/PPR-DVC pathways in the brainstem [99, 103]. The hypothermia resulting from cold
exposure induces Fos expression in the Rpa, Rob, PPR and DVC neurons and enhances
brainstem TRH gene expression, especially in the Rpa and Rob [99, 104, 105]. These brainstem
changes are with strongly concomitant activation of gastric myenteric neurons through the
excitement of vagal-nicotinic pathways and therefore responsible for the vagal-mediated
increases of gastric acid secretion/motility and sympathetic-mediated decrease of mucosal
blood flow, leading to gastric ulcer formation [102, 106-108]. Cold exposure induced gastric
ulceration and increased gastric emptying were prevented by icv injection of TRH antiserum
or antisense oligodeoxynucleotides of TRH receptor, respectively [109, 110].
Brainstem TRH gene expression is influenced by thyroid hormone levels in a feedback
regulatory manner. Thyroidectomy increases TRH mRNA levels in the raphe nuclei and the
effect is reversed by thyroid hormone replacement [100]. This finding indicates that abnormal
brainstem TRH gene expression and altered TRH regulation of sympathovagal efferent
outflow may be involved in the autonomic disorders observed in hypo- or hyperthyroidism.
Our recent studies demonstrated that brainstem TRH is involved in food intake regulation.
Intracisternal injection of the stable TRH analog RX77368 (7.5-25 ng) dose-dependently
stimulated solid food intake by 2.4- to 3-fold in freely fed rats, an effect that lasted for 3 hours.
By contrast, RX77368 at 25 ng injected into the lateral ventricle induced a delayed and
insignificant orexigenic effect only in the first hour. In pentobarbital-anesthetized rats,
intracisternal injection of TRH analog (50 ng) induced a significant bi-peak increase in serum
total ghrelin levels from the basal of 8.7 ± 1.7 ng/ml to 13.4 ± 2.4 ng/ml at 30 min and 14.5 ± 2.0
ng/ml at 90 min, which was prevented by either bilateral vagotomy (-60 min) or atropine
pretreatment (2 mg/kg, -30 min) but magnified by bilateral adrenalectomy (-60 min). TRH
analog induced food intake in freely fed rats was abolished by either peripheral atropine or
ghrelin receptor antagonist (D-Lys-3)-GHRP-6 (10 μmol/kg), or intracisternal Y1 receptor
antagonist 122PU91 (10 nmol/5 μl). Brainstem TRH mRNA and TRH receptor1 mRNA
increased by 57-58% and 33-35% in 24-48 h fasted rats and returned to the fed levels after a 3
hour re-feeding. Natural food intake in overnight fasted rats was significantly reduced by
intracisternal TRH antibody, Y1 antagonist, and peripheral atropine. These data establish a
physiological role of brainstem TRH in vagal-ghrelin-mediated stimulation of food intake,
which involves interaction with brainstem Y1 receptors [49].
3.4. Interaction of TRH with other neurotransmitters and neuropeptides in the DVC
The TRH-synthesizing neurons in brainstem raphe nuclei contain other neuropeptides and
neurotransmitters, such as substance P (SP) and serotonin (5-HT). These transmitters/peptides
co-release with TRH in the raphe projections innervating the target autonomic-regulatory
neurons. In the DVC, 5-HT potentiates and SP suppresses the vagal-activating action of TRH
[111, 112].
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3.5. Upper GI afferent signals influence TRH regulation of vagal efferent activity
The upper gut mechano-/chemo- signals and their impact on ascending sympathetic-vagal
afferents are crucial information for the brain to adjust sympathetic-vagal efferent functions
involved in controlling glucose and energy homeostasis [113, 114]. GI peptides, such as
cholecystokinin (CCK) and secretin, released from the proximal small intestine, and peptide
YY (PYY) and glucagon-like peptide-1 (GLP-1), released from the hindgut, all appear to
accomplish their gastric/pancreatic regulatory functions through both the humoral route and
the vagus nerve [113]. These peptides modulate, mostly inhibit, efferent vagal outflow at least
partly through brainstem vago-vagal reflexive neurocircuits that initiated with stimulating
vagal afferent pathways, acting on either vagal afferent terminals in the GI enteric plexuses,
vagal afferent neurons in the nodose ganglions that express all the relevant receptors for these
gut hormones, or brainstem AP/NTS neurons, where receptors of these peptides are localized
[113, 114]. Glucose itself is an activator of vagal afferents [114]. In addition, information of
glucose metabolism in the liver is sent to the brainstem via the afferent fibers in the hepatic
vagal branch. Sensors localized in the portal vein pass nutrition signals to the brain through
sympathetic-spinal pathways [113, 114]. Of particular noticeable, the vagal-efferent activation
by brainstem TRH is inhibited by these signals from proximal gut. We have found that
intraduodenal infusion of lipid or intravenous infusion of glucose, CCK, secretin, or PYY
inhibits intracisternal TRH-induced gastric acid secretion that is mediated by vagal efferent
activation [115-117].
Collectively, research findings show that the TRH containing raphe-DVC pathways and raphe-
IML pathways play important physiological roles in maintaining metabolic homeostasis,
through balancing sympathovagal outflow that controls multisystemic visceral organs.
4. Sympathovagal imbalance is the linchpin of T2D pathophysiology
Relative to healthy peers, diabetic patients have increased sympathetic and decreased
parasympathetic activity that appears to be present at early stages of metabolic impairment,
regardless of the presence or absence of autonomic neuropathy [118-121]. T2D patients have
higher resting muscle sympathetic nerve activity burst incidence and arterial norepinephrine
levels, lower plasma norepinephrine clearance and reduced neuronal reuptake, compared
with obese metabolic syndrome patients [122]. The progression from obesity to T2D is
associated with increased central sympathetic drive, blunted sympathetic responsiveness, and
altered norepinephrine disposition [122]. Unbalanced autonomic function leads to the
development of diabetes and its complications, including hypertension [123], increased risk
of cardiovascular events such as arrhythmia [4, 124, 125], enhanced activity of hypothalamus-
pituitary-adrenal axis [126], potentiated hepatic glucose output [127], suppression of insulin
release [128], insulin resistance [6], lipemia and increased visceral fat [129], chronic renal failure
[130], reduced gastric secretion/motility and altered gut hormone secretion [131, 132]. More‐
over, sympathetic overactivity may be a contributing factor to the development of T2D in non-
obese men [133]. Vagal impairment contributes significantly to the predominance of
sympathetic activity in T2D [4].
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4.1. The vagal regulation of visceral function is altered by abnormal blood glucose levels in
T2D
Converging evidence suggests that hyper- or hypoglycemia affects GI functions by influencing
vagal-cholinergic outflow to the viscera. GI functions stimulated by vagal efferent activation,
such as sham feeding-induced pancreatic polypeptide (PP) release and gastric acid secretion,
were remarkably reduced in humans during hyperglycemia [134]. In the rat, experimental
diabetes lowered gastric acid secretion, which did not decrease further after vagotomy [135].
Hyperglycemia induced by intravenous glucose infusion completely prevented the gastric
acid secretion stimulated by intracisternal TRH analog [115]. In contrast to hyperglycemia,
insulin-hypoglycemia induces central-vagal stimulus of upper GI functions and has been
widely used to test vagus nerve integrity [136-139]. These findings establish the mediating role
of the vagus nerve in GI functional alternations induced by altered glucose metabolism.
Gastroparesis is a common complication of diabetes [140]. Gastric acid secretion is markedly
lower and gastric emptying abnormalities occur in about 30-50% of diabetic patients [141-144].
Although morphological changes in the vagus nerve were identified in diabetic patients [145],
many observations indicate that hyperglycemia itself may play a major role in the abnormal
GI motility of T2D patients, in addition to the traditionally-attributed irreversible autonomic
neuropathy [143, 146]. Acute hyperglycemia causes reversible motility impairment in the GI
tract in both healthy subjects and in diabetic patients and animals [147-151]. Delay in gastric
emptying is observed within one week after streptozotocin treatment in rats, when there is no
autonomic neuropathy developed [152]. Even changes in blood glucose levels within the
normal postprandial range significantly impact gastric emptying in both normal subjects and
diabetic patients [153]. These observations show that hyperglycemia in diabetes can influence
vagal-mediated visceral functions through functional alteration, in addition to morphological
damage, of the vagus nerve.
4.2. Sympathovagal imbalance in T2D suppresses insulin secretory response to glucose
T2D Patients frequently lose the first phase insulin release that is mainly triggered by vagal
activation [154]. The vagal-mediated acute insulin response to glucose is absent in those with
glucose levels above 115 mg/dL [155]. In fact, after intravenous glucose infusion, both the first
and second phases of insulin secretion are impaired in T2D patients [156]. The impaired second
phase insulin secretion may result from reduced incretin secretory response and the reduction
of absolute incretin effect in T2D [156-158], both can be attributed to impaired vagal efferent
activity [159]. The impaired vagal function reduces the proliferation of pancreatic islet β-cells,
resulting in an approximately 60% reduction in β-cell mass in T2D patients [38, 160]. With
increasing duration of T2D, the decrease of postprandial insulin secretion becomes more
prominent [161]. The contribution of sympathetic overactivity to the inhibition of insulin
secretion in T2D was evidenced in a patient, who underwent a spinal-sympathetic blockage
for treating a disorder that was not directly related to diabetes but resulted in a dramatic 50%
decrease in her insulin need [162]. Adrenalectomy increases basal insulin secretion in rats [82].
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4.3. Sympathetic hyperactivity contributes to cardiovascular diseases in T2D
Cardiovascular disease is the leading cause of mortality in patients with T2D. T2D patients
have a high incidence of hypertension and nonischemic heart failure, and worse outcomes in
acute cardiovascular events compared to non-diabetic controls [163, 164]. A key mechanism
underlying cardiovascular disorders is an increase in sympathetic nerve activity [73, 165], in
addition to pathological cardiovascular changes due to inflammation and over-activity of the
renin-angiotensin system [164, 166-168], which are associated with altered sympathovagal
function as well. The cardiac vagal and sympathetic nerve functions are both abnormal in T2D
patients, but particularly shown as decreased cardiac vagal baroreflex sensitivity [169]. These
autonomic dysregulation contribute to increased blood pressure (BP), cardiac arrhythmias and
atrial fibrillation, and the resulting progression to heart failure [4, 118, 170-173]. The attenuated
sympathetic response to hypotension may contribute directly to mortality in diabetes and
cardiovascular disease [174]. Autonomic dysfunction has become one of the most powerful
predictor of risk for cardiac mortality in T2D patients [169, 175].
5. Brainstem TRH dysfunction is involved in the sympathovagal imbalance
in T2D: Studies with T2D Goto-Kakizaki (GK) rats
Our lab in the last 10 years used a T2D rat model and combined systemic T2D pathophysiology
and autonomic neuroscience to assess the role of brainstem TRH in the central mechanism
responsible for the sympathovagal imbalance in T2D.
5.1. GK rat is a suitable animal model for studying sympathovagal imbalance in T2D
The GK rat is an extensively studied polygenic model of non-obese T2D that was obtained by
selective breeding of individuals with glucose intolerance from a non-diabetic Wistar rat
colony [176,177]. GK rats are used to dissect genetic etiology of T2D [178,179], and exhibit well-
characterized features typical of human T2D, such as fasting hyperglycemia, impaired insulin-
secretory response to glucose, reduced β-cell mass, chronic inflammation, disruption of hepatic
lipid metabolism, hypertension, and insulin resistance [97, 176, 178, 180, 181]. GK rats and
human T2D share similar late complications, such as neuropathy, nephropathy, and cardio‐
vascular disorders including heart failure [180, 182-184]. Glucose-stimulated insulin release
was reduced by 90% in the first phase and by 75% in the second phase in GK rats [185]. Vagal-
dependent increase of islet blood flow, which is required for glucose-induced insulin secretion,
is diminished in GK rats [186]. Carbachol, an agonist for muscarinic acetylcholine receptors,
fully normalizes insulin secretion in GK rats responding to 16.7 mmol/L glucose through an
effect abolished by atropine [187].
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5.2. Impaired brainstem TRH action on activating vagal efferents in T2D GK rats
5.2.1. Increased fat content and elevated serum leptin levels in T2D GK rats
Higher amounts of visceral fat is a sign of a high ratio of sympathetic vs parasympathetic
reactivity [129]. We measured the lean and fat body mass quantities in awake rats by non-
invasive magnetic resonance imaging. Compared to Wistar rats with same body weight, GK
rats have doubled fat mass and significantly less lean mass. During rat growth from 285 g to
320 g, the increase in Wistar rats is mainly lean weight while that in GK rats is mainly fat
weight. Coinciding with this finding, serum leptin levels elevated in GK rats in normally
feed, fast, and refeed status. Hyperleptinemia is associated with increased sympathetic ac‐
tivity as leptin increases sympathetic nerve activity to influence cardiovascular, renal, mus‐
cle, endocrine, and adrenal gland functions [188, 189].
5.2.2. Absence of vagally mediated gastric acid response to intracisternal TRH analog in T2D GK rats
TRH is a physiological stimulator on DMV neurons to induce a vagally mediated excitation
of gastric secretory/motility functions [80]. The well-known gastric acid-stimulatory effect of
intracisternal injection of TRH analog was totally absent in T2D GK rats, indicating that
TRH action in the DMV to activate vagal efferent outflow is severely damaged in GK rats.
5.2.3. Potentiated hyperglycemic and suppressed insulin early-phase responses to TRH analog injected
intracisternally, intrathecally into the subarachnoid space at the thoracic 8-11 level, or microinjected
into the RVLM in T2D GK rats
TRH analog RX77368 (50 ng) injected intracisternally induced markedly greater hyperglyce‐
mic and weaker insulin responses in GK rats than in Wistar rats. Bilateral vagotomy blocked
RX77368-induced insulin secretion while adrenalectomy abolished its hyperglycemic effect.
In adrenalectomized GK but not Wistar rats, RX77368 dramatically increased serum insulin
levels by 6.5-fold and decreased blood glucose levels from 154 to 98 mg%; these changes
were prevented by simultaneous vagotomy. These results indicate that central-vagal activa‐
tion-induced insulin secretion is susceptible in T2D GK rats and the dominant sympathetic-
adrenal response to brainstem TRH plays a suppressing role on vagal-mediated insulin
secretion. This unbalanced sympathovagal activation by medullary TRH may contribute to
the impaired insulin secretion in T2D [82].
TRH analog RX77368 injected intrathecally or microinjected into the RVLM, the TRH action
sites for activating the sympathetic efferent function, induced a significantly potentiated hy‐
perglycemic response and an impaired first hour insulin response in T2D GK rats, compared
to Wistar rats, indicating a sympathetic overactivation together with an impaired vagal
counterregulatory response to hyperglycemia in GK rats [69, 82].
5.2.4. Brainstem TRH-triggered cardioacceleration results in death from congestive heart failure in T2D
GK rats, showing diminished vagal efferent function in baroreceptor reflex
In comparison with Wistar rats, GK rats exhibited basal systolic hypertension (152 ± 2 mmHg)
and a significantly potentiated, dose-related hypertensive response to intracisternal injection
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of TRH analog RX77368 (10-60 ng). In GK rats only, intracisternal RX77368 (30-60 ng) markedly
increased heart rate (+88 bpm) and induced acute cardiac mortality (100%) resulting from
congestive heart failure, concurrent with extreme hyperglycemia (>480 mg%), increased
plasma H2O2 and 8-isoprostane, and increased heart mRNA levels of NADPH oxidase 4 and
vascular cell adhesion molecule-1, which are the oxidative stress and inflammation markers.
GK rats also had elevated basal levels of plasma epinephrine, higher adrenal gene expression
of epinephrine-synthesizing enzymes tyrosine hydroxylase and dopamine β-hydroxylase, and
greater responses of plasma catecholamines and the adrenal enzymes to intracisternal TRH
analog, compared to Wistar rats. Pretreatment with the nicotine receptor blocker hexametho‐
nium prevented intracisternal TRH analog induced hypertensive and tachycardic responses,
and cardiac mortality in GK rats. The α-receptor blockage with phentolamine abolished the
hypertensive response but enhanced tachycardia (+160 bpm), and reduced mortality by 50%.
The angiotensin II type 1 receptor antagonist irbesartan prevented intracisternal RX77368-
induced increases in blood pressure, heart rate, and mortality. These findings indicate that
sympathetic overactivation triggered by brainstem TRH and the lack of effective vagal
counterregulation contribute to the cardiovascular morbidity and mortality in T2D, which
involves heightened cardiac inflammation and peripheral oxidative stress responses to the
sympathetic drive and a mediating role of renin-angiotensin system [97]. The cardiovascular
autonomic imbalance in GK rats further confirms a diminished vagal-activating function of
brainstem TRH, which is responsible for the damaged vagal arm function in the baroreceptor
reflex.
6. Summary and perspectives
Using the T2D GK rat model, we found a damaged brainstem TRH action on activating the
vagal efferent functions, which contributes to reveal the central mechanism of the sympatho‐
vagal imbalance in T2D. Further studies are warranted to investigate in the cellular and
molecular levels of the abnormal vagal motor neuronal functions in T2D, such as insulin and
TRH signaling in the DVC neurons.
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